Safety of extended treatment with Anakinra in patients with rheumatoid arthritis

University of Texas Southwestern Medical Center at Dallas, Radiant Research, 5939 Harry Hines Boulevard, Dallas, TX 75235, USA.
Annals of the Rheumatic Diseases (Impact Factor: 10.38). 09/2006; 65(8):1006-12. DOI: 10.1136/ard.2005.048371
Source: PubMed


To determine the safety profile of anakinra after extended exposure in a diverse clinical trial population of patients with rheumatoid arthritis.
A six month, randomised, double blind phase comparing anakinra (100 mg/day) with placebo was followed by open label anakinra treatment for up to three years in patients with rheumatoid arthritis. Concomitant non-steroidal anti-inflammatory drugs, corticosteroids, and other disease modifying antirheumatic drugs were permitted.
In all 1346 patients with rheumatoid arthritis received anakinra for up to three years. Patients had varying levels of disease severity, concomitant drug use, and comorbid conditions. Cumulative, exposure adjusted event (EAE) rates for all adverse events (AEs), serious AEs, and deaths were similar during each year of anakinra treatment; the overall rate (0 to 3 years) was similar to that observed for controls during the blinded phase. The most frequent AEs were injection site reactions (122.26 events/100 patient-years), rheumatoid arthritis progression (67.80 events/100 patient-years), and upper respiratory infections (26.09 events/100 patient-years). The EAE rate of serious infections was higher for patients treated with anakinra for 0 to 3 years (5.37 events/100 patient-years) than for controls during the blinded phase (1.65 events/100 patient-years). However, if the patient was not receiving corticosteroid treatment at baseline, the serious infection rate was substantially lower (2.87 event/100 patient-years). The overall incidence of malignancies was consistent with expected rates reported by SEER. Neutralising antibodies developed in 25 patients, but appeared to be transient in 12; neutralising antibody status did not appear related to occurrence of malignancies or serious infections. There were no clinically significant trends in laboratory data related to anakinra.
Anakinra is safe and well tolerated for up to three years of continuous use in a diverse population of patients with rheumatoid arthritis.

1 Follower
17 Reads
  • Source
    • "Inhibition of the IL-1b pathway by a specific IL-1 receptor antagonist is present endogenously in cartilage in physiological condition, and is an already used strategy in clinic to prevent cartilage degradation during osteoarthritis pathogenesis [32] [33]. One of the classically used molecules in therapy is the recombinant anakinra, an analog of the physiological human IL-1Ra [34]. Reversion by anakinra of IL-1b effect in differentiated hMADS cells, demonstrated clearly that these cells can be used in pharmacological screening in order to found new anti-arthrosic compounds. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chondrogenesis has been widely investigated in vitro using bone marrow-derived mesenchymal stromal cells (BM-MSCs) or primary chondrocytes. However, their use raises some issues partially circumvented by the availability of Adipose tissue-derived MSCs. Herein; we characterized the chondrogenic potential of human Multipotent Adipose-Derived Stem (hMADS) cells, and their potential use as pharmacological tool. hMADS cells are able to synthesize matrix proteins including COMP, Aggrecan and type II Collagen. Furthermore, hMADS cells express BMP receptors in a similar manner to BM-MSC, and BMP6 treatment of differentiated cells prevents expression of the hypertrophic marker type X Collagen. We tested whether IL-1β and nicotine could impact chondrocyte differentiation. As expected, IL-1β induced ADAMTS-4 gene expression and modulated negatively chondrogenesis while these effects were reverted in the presence of the IL-1 receptor antagonist. Nicotine, at concentrations similar to those observed in blood of smokers, exhibited a dose dependent increase of Aggrecan expression, suggesting an unexpected protective effect of the drug under these conditions. Therefore, hMADS cells represent a valuable tool for the analysis of in vitro chondrocyte differentiation and to screen for potentially interesting pharmacological drugs.
    Biochemical and Biophysical Research Communications 10/2013; 440(4). DOI:10.1016/j.bbrc.2013.10.012 · 2.30 Impact Factor
  • Source
    • "IL-6– and IL-1–targeted therapies have been used clinically to treat various diseases, such as rheumatoid arthritis [35], [36] and Castleman’s disease [37]. These therapies may have additional clinical applications in the treatment of gastric cancer. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Interleukin-6 (IL-6) is a pleiotropic cytokine that affects various functions, including tumor development. Although the importance of IL-6 in gastric cancer has been documented in experimental and clinical studies, the mechanism by which IL-6 promotes gastric cancer remains unclear. In this study, we investigated the role of IL-6 in the epithelial-stromal interaction in gastric tumorigenesis. Immunohistochemical analysis of human gastritis, gastric adenoma, and gastric cancer tissues revealed that IL-6 was frequently detected in the stroma. IL-6-positive cells in the stroma showed positive staining for the fibroblast marker α-smooth muscle actin, suggesting that stromal fibroblasts produce IL-6. We compared IL-6 knockout (IL-6(-/-)) mice with wild-type (WT) mice in a model of gastric tumorigenesis induced by the chemical carcinogen N-methyl-N-nitrosourea. The stromal fibroblasts expressed IL-6 in tumors from WT mice. Gastric tumorigenesis was attenuated in IL-6(-/-) mice, compared with WT mice. Impaired tumor development in IL-6(-/-) mice was correlated with the decreased activation of STAT3, a factor associated with gastric cancer cell proliferation. In vitro, when gastric cancer cell line was co-cultured with primary human gastric fibroblast, STAT3-related genes including COX-2 and iNOS were induced in gastric cancer cells and this response was attenuated with neutralizing anti-IL-6 receptor antibody. IL-6 production from fibroblasts was increased when fibroblasts were cultured in the presence of gastric cancer cell-conditioned media. IL-6 production from fibroblasts was suppressed by an interleukin-1 (IL-1) receptor antagonist and siRNA inhibition of IL-1α in the fibroblasts. IL-1α mRNA and protein were increased in fibroblast lysate, suggesting that cell-associated IL-1α in fibroblasts may be involved. Our results suggest the importance of IL-6 mediated stromal-epithelial cell interaction in gastric tumorigenesis.
    PLoS ONE 04/2013; 8(4):e60914. DOI:10.1371/journal.pone.0060914 · 3.23 Impact Factor
  • Source
    • "However, despite a long history of investigation, no treatments that effectively reverse or prevent the memory deficits associated with inflammation are available. General inhibition of the inflammatory response and specific blocking of IL-1b activity by inhibiting the membrane-bound type 1 IL-1 receptors are impractical approaches because of the risks of infection and delayed wound healing (Fleischmann et al., 2006). Moreover , low basal levels of IL-1b in the hippocampus play a physiological role in maintaining normal memory performance (Yirmiya and Goshen, 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Systemic inflammation causes learning and memory deficits through mechanisms that remain poorly understood. Here, we studied the pathogenesis of memory loss associated with inflammation and found that we could reverse memory deficits by pharmacologically inhibiting alpha5-subunit-containing gamma-aminobutyric acid type A (alpha5GABA(A)) receptors and deleting the gene associated with the alpha5 subunit. Acute inflammation reduces long-term potentiation, a synaptic correlate of memory, in hippocampal slices from wild-type mice, and this reduction was reversed by inhibition of alpha5GABA(A) receptor function. A tonic inhibitory current generated by alpha5GABA(A) receptors in hippocampal neurons was increased by the key proinflammatory cytokine interleukin-1beta through a p38 mitogen-activated protein kinase signaling pathway. Interleukin-1beta also increased the surface expression of alpha5GABA(A) receptors in the hippocampus. Collectively, these results show that alpha5GABA(A) receptor activity increases during inflammation and that this increase is critical for inflammation-induced memory deficits.
    Cell Reports 09/2012; 2(3-3):488-96. DOI:10.1016/j.celrep.2012.08.022 · 8.36 Impact Factor
Show more


17 Reads
Available from